

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

September 13, 2024

Dennis M. Lanfear President and Chief Executive Officer Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, California 94065

> Re: Coherus BioSciences, Inc. Definitive Proxy Statement on Schedule 14A Filed April 15, 2024 File No. 001-36721

Dear Dennis M. Lanfear:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Disclosure Review Program

cc: Max Brunner, Esq.